When you stop taking Avastin (bevacizumab), two things happen simultaneously: side effects from the drug begin to fade, and its cancer-suppressing effects wear off. The drug has a long half-life of roughly 20 days in humans, meaning it takes several weeks to fully clear your system. During that window, some changes are gradual and welcome, while others require careful monitoring by your oncology team.
How Long Avastin Stays in Your Body
Avastin doesn’t leave your bloodstream quickly. With a half-life of about 20 days, half the drug is still circulating three weeks after your last infusion. It generally takes four to five half-lives for a medication to be considered fully eliminated, which means trace amounts of Avastin can remain in your system for roughly three to four months after your final dose.
This slow clearance is why the FDA’s prescribing information specifies waiting at least 28 days before any elective surgery and at least 28 days after surgery before restarting. Some surgical guidelines are even more conservative, recommending a wait of six to eight weeks after the last dose to allow wound healing processes to fully recover.
Side Effects That Improve After Stopping
Many of Avastin’s common side effects, including nosebleeds, fatigue, headaches, and appetite changes, are temporary and typically begin improving within days to weeks of the final infusion. The timeline varies from person to person, but most people notice gradual relief as the drug clears.
High blood pressure is one of the most well-documented side effects of Avastin, and it resolves in the majority of patients after treatment ends. In a study of gynecologic cancer patients who developed high blood pressure on bevacizumab, about 82% saw their blood pressure return to normal, with a median time to resolution of roughly three months (87 days). For some patients it resolved in under a week; for others it took closer to eight months. If you started blood pressure medication during treatment, your doctor will likely taper it down as your readings improve.
Kidney-related side effects are less predictable. Avastin can cause protein to leak into the urine, a condition called proteinuria. In most cases this is mild and resolves on its own, but in rare severe cases, kidney problems can persist even after the drug is stopped. Among patients who developed the most serious form (nephrotic syndrome), some required ongoing treatment including dialysis.
The Rebound Effect on Tumor Growth
This is the concern that weighs most heavily on patients and oncologists alike. Avastin works by blocking a protein called VEGF that tumors use to build new blood vessels and feed their growth. When you stop the drug, VEGF signaling resumes, and the blood vessel growth that was suppressed can come back rapidly.
Research published in Nature Communications found that stopping anti-VEGF therapy can trigger what scientists call a “rebound effect.” During treatment, tumors and even healthy tissues become starved of oxygen. The body compensates by ramping up production of growth signals, including VEGF and other factors that Avastin doesn’t block. When the drug is removed, this pent-up signaling can drive rapid blood vessel regrowth, potentially creating conditions that favor tumor spread. In animal models, this revascularization of liver tissue after drug cessation provided a structural pathway for cancer metastasis.
This doesn’t mean stopping Avastin will automatically cause your cancer to spread. It means the transition off the drug is a period your oncologist monitors closely, and the decision to stop is weighed carefully against the risks of continuing.
What This Looks Like in Brain Cancer
The rebound concern is especially relevant in glioblastoma, where Avastin is commonly used for recurrent disease. A study of 37 glioblastoma patients found distinct patterns when the cancer progressed on or after bevacizumab. About 46% had regrowth at the original tumor site, 16% developed new tumors in different locations, and 35% showed a pattern of diffuse, invasive tumor spread that didn’t light up on standard MRI scans the way typical tumors do.
That last pattern is particularly concerning. Anti-VEGF therapy can push tumor cells to invade surrounding brain tissue by co-opting existing blood vessels rather than building new ones. This creates a more diffuse, harder-to-detect form of disease. Tissue samples from these patients showed significantly elevated markers of oxygen deprivation, confirming that the biological stress of treatment was reshaping how the tumor behaved. Patients with this nonenhancing pattern of recurrence tended to have shorter survival after bevacizumab was discontinued.
Why Maintenance Therapy Matters
For certain cancers, the data strongly supports continuing Avastin as maintenance therapy rather than stopping after the initial chemotherapy rounds. A study of advanced and recurrent cervical cancer found striking differences between patients who continued bevacizumab and those who stopped. Patients on maintenance therapy had a median progression-free survival of 18.7 months compared to 9.6 months for those who stopped. Overall survival was even more dramatic: 39.9 months versus 15.5 months.
At the three-year mark, 30% of patients on maintenance Avastin were still recurrence-free, compared to just 3.6% of those who discontinued. And 58.7% of maintenance patients were still alive at three years, versus 20.7% of those who stopped. In this study, continuing bevacizumab was the single strongest predictor of longer progression-free survival.
These numbers come from cervical cancer specifically, and the benefit of maintenance therapy varies by cancer type. But they illustrate why the decision to stop Avastin is rarely casual. Your oncologist considers your cancer type, how well you’ve responded, the side effects you’re experiencing, and whether the ongoing benefit outweighs the risks of continued treatment.
Wound Healing and Surgery After Stopping
Avastin suppresses the formation of new blood vessels, which is exactly what your body needs to heal wounds. This means any surgery, dental procedure, or injury during or shortly after treatment carries a higher risk of complications like delayed healing, wound dehiscence (where an incision reopens), or bleeding.
The FDA recommends a minimum 28-day gap between your last Avastin infusion and elective surgery, and the same gap after surgery before restarting. Some experts recommend a longer window of six to eight weeks, reasoning that two half-lives provides a more comfortable margin of safety. If you’re planning any procedure, even a dental extraction, let both your oncologist and the surgeon or dentist know when your last infusion was.
What Recovery Feels Like in Practice
For most people, the weeks after stopping Avastin bring a gradual return of energy and a fading of treatment-related symptoms. Blood pressure normalizes over one to three months in most cases. Minor side effects like nosebleeds and mouth sores tend to clear within a few weeks. Your body’s ability to heal cuts and bruises improves as blood vessel function returns to normal.
At the same time, you’ll likely have more frequent imaging scans in the months following discontinuation. Your oncology team will be watching for any signs of disease progression, particularly in the first few months when the rebound risk is highest. This monitoring period is a normal part of transitioning off anti-angiogenic therapy, not a sign that something has gone wrong. The goal is catching any changes early, when the most options are still available.